Status: Recruiting

Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration

A multicenter clinical study to evaluate the safety, PK characteristics, immunogenicity characteristics, and PD characteristics of IBI3013 in healthy trial participants and active non-segmental vitiligo trial participants and severe alopecia areata trial participants. The study is divided into 2 parts, with Part 1 involving healthy trial participants lasting up to 24 weeks, and Part 2 involving active non-segmental vitiligo trial participants and severe alopecia areata trial participants lasting up to 48 weeks.

Participants needed: 160

Trial details

Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Innovent Biologics (Suzhou) Co. Ltd.Updated: Apr 28, 2026Locations: 1

Eligibility criteria

Part 1 - Healthy trial participants: Understand and voluntarily sign the informe... [+9]

All participants: Those who are allergic to any component of IBI3013; [+14]

Active Non-segmental Vitiligo

Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration